Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

BACKGROUND: Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with MG. Here, we investigate whether current immunosuppressive therapy (IST) influences the risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stascheit, Frauke, Grittner, Ulrike, Hoffmann, Sarah, Mergenthaler, Philipp, Schroeter, Michael, Ruck, Tobias, Pawlitzki, Mark, Blaes, Franz, Kaiser, Julia, Schara, Ulrike, Della-Marina, Adela, Thieme, Andrea, Hagenacker, Tim, Jacobi, Christian, Berger, Benjamin, Urban, Peter P., Knop, Karl Christian, Schalke, Berthold, Lee, De-Hyung, Kalischewski, Petra, Wiendl, Heinz, Meisel, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512984/
https://www.ncbi.nlm.nih.gov/pubmed/36166068
http://dx.doi.org/10.1007/s00415-022-11389-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512984/
https://www.ncbi.nlm.nih.gov/pubmed/36166068
http://dx.doi.org/10.1007/s00415-022-11389-0

Ejemplares similares